Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: Systematic review and meta-analysis

Clinical Endocrinology

Volumn 81, Issue 5, 2014, Pages 642-651

  Niemeijer, N D ^a   Alblas, G ^a   Van Hulsteijn, L T ^a   Dekkers, O M ^a   Corssmit, E P M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; CYCLOPHOSPHAMIDE; DACARBAZINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; GASTROINTESTINAL TOXICITY; HORMONE RESPONSE; HUMAN; META ANALYSIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; ADRENAL GLAND NEOPLASMS; METABOLISM; PATHOLOGY;

ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATECHOLAMINES; CYCLOPHOSPHAMIDE; DACARBAZINE; HUMANS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; TUMOR BURDEN; VINCRISTINE;

EID: 84912070787     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12542     Document Type: Article

References (31)

1. De Lellis, R.A., Lloyd, R.V., Heitz, P.U., et al,. (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. IARC, Press, Lyon.
2. Pacak, K., Keiser, H., &, Eisenhofer, G., (2005) Pheochromocytoma. In:, L.J. De Groot, J.L. Jameson, eds. Textbook of Endocrinology. Elsevier Saunders Inc, Philadelphia, 2501-2534.
3. Chrisoulidou, A., Kaltsas, G., Ilias, I., et al,. (2007) The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocrine Related Cancer, 14, 569-585.
4. Granger, J.K., &, Houn, H.Y., (1990) Head and neck paragangliomas: a clinicopathologic study with DNA flow cytometric analysis. Southern Medical Journal, 83, 1407-1412.
5. Linnoila, R.I., Keiser, H.R., Steinberg, S.M., et al,. (1990) Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Human Pathology, 21, 1168-1180.
6. Scholz, T., Schulz, C., Klose, S., et al,. (2007) Diagnostic management of benign and malignant pheochromocytoma. Experimental and Clinical Endocrinology & Diabetes, 115, 155-159.
7. Eisenhofer, G., Bornstein, S.R., Brouwers, F.M., et al,. (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine Related Cancer, 11, 423-436.
8. Fitzgerald, P.A., Goldsby, R.E., Huberty, J.P., et al,. (2006) Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Annals of the New York Academy of Sciences, 1073, 465-490.
9. Goldstein, R.E., O'Neill, J.A. Jr, Holcomb, G.W. III, et al,. (1999) Clinical experience over 48 years with pheochromocytoma. Annals of Surgery, 229, 755-764.
10. Loh, K.C., Fitzgerald, P.A., Matthay, K.K., et al,. (1997) The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. Journal of Endocrinological Investigation, 20, 648-658.
11. Forrer, F., Riedweg, I., Maecke, H.R., et al,. (2008) Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 52, 334-340.
12. van Hulsteijn, L.T., Niemeijer, N.D., Dekkers, O.M., et al,. (2014) I-MIBG therapy for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clinical Endocrinology, 80, 487-501.
13. Keiser, H.R., Goldstein, D.S., Wade, J.L., et al,. (1985) Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension, 7, 18-24.
14. Averbuch, S.D., Steakley, C.S., Young, R.C., et al,. (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Annals of Internal Medicine, 109, 267-273.
15. Finklestein, J.Z., Klemperer, M.R., Evans, A., et al,. (1979) Multiagent chemotherapy for children with metastatic neuroblastoma: a report from Childrens Cancer Study Group. Medical and Pediatric Oncology, 6, 179-188.
16. Scholz, T., Eisenhofer, G., Pacak, K., et al,. (2007) Clinical review: current treatment of malignant pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 92, 1217-1225.
17. Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al,. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer, 45, 228-247.
18. Hamza, T.H., van Houwelingen, H.C., &, Stijnen, T., (2008) The binomial distribution of meta-analysis was preferred to model within-study variability. Journal of Clinical Epidemiology, 61, 41-51.
19. DerSimonian, R., &, Laird, N., (1986) Meta-analysis in clinical trials. Controlled Clinical Trials, 7, 177-188.
20. Chang, B.H., Waternaux, C., &, Lipsitz, S., (2001) Meta-analysis of binary data: which within study variance estimate to use? Statistics in Medicine, 20, 1947-1956.
21. Rao, F., Keiser, H.R., &, O'Connor, D.T., (2000) Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension, 36, 1045-1052.
22. Ayala-Ramirez, M., Feng, L., Habra, M.A., et al,. (2012) Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer, 118, 2804-2812.
23. Huang, H., Abraham, J., Hung, E., et al,. (2008) Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer, 113, 2020-2028.
24. Szalat, A., Fraenkel, M., Doviner, V., et al,. (2011) Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center. Endocrine, 39, 160-166.
25. Tanabe, A., Naruse, M., Nomura, K., et al,. (2013) Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Hormones & Cancer, 4, 103-110.
26. Dekkers, O.M., Egger, M., Altman, D.G., et al,. (2012) Distinguishing case series from cohort studies. Annals of Internal Medicine, 156, 37-40.
27. Hescot, S., Leboulleux, S., Amar, L., et al,. (2013) One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. Journal of Clinical Endocrinology and Metabolism, 98, 4006-4012.
28. Joshua, A.M., Ezzat, S., Asa, S.L., et al,. (2009) Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 94, 5-9.
29. Jimenez, C., Cabanillas, M.E., Santarpia, L., et al,. (2009) Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. Journal of Clinical Endocrinology and Metabolism, 94, 386-391.
30. Ayala-Ramirez, M., Chougnet, C.N., Habra, M.A., et al,. (2012) Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. Journal of Clinical Endocrinology and Metabolism, 97, 4040-4050.
31. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al,. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute, 92, 205-216.